BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 25, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2014

View Archived Issues

Nanoparticle-mediated in vivo delivery of therapeutic siRNAs

Read More

Eisai establishes collaboration to identify anti-Wolbachia drugs to treat filariasis

Read More

Adocia reports data for combination of long-acting and fast-acting insulin

Read More

New monoclonal antibodies for the treatment of botulism disclosed

Read More

4SC Discovery collaborates with Heidelberg University Hospital on new malaria drug

Read More

Novan reports phase II data for SB-204

Read More

World Tuberculosis Day News: Research shows feasibility of diagnosis via biomarkers in sputum

Read More

Phase IIb topline results for cariprazine adjunctive treatment in major depressive disorder

Read More

Novartis' BCR-ABL kinase inhibitor ABL-001 enters clinical study

Read More

Global Health Innovative Technology Fund grants millions for infectious diseases research

Read More

Novel ITK inhibitors divulged by Principia Biopharma

Read More

Researchers at Amgen disclose novel GKRP/GK interaction inhibitors

Read More

Merck KGaA presents novel DDR2 inhibitors

Read More

Results from first-in-human study of a direct thrombin inhibitor, CTB-001

Read More

Geron reports Myelofibrosis IST trial placed on partial clinical hold

Read More

Biotie to regain global rights to tozadenant

Read More

Endocyte reports results from phase IIb study of vintafolide in NSCLC

Read More

ArevaMed presents phase I data for 212Pb-TCMC-trastuzumab

Read More

FDA approves Otezla for psoriatic arthritis

Read More

Significant improvements in psoriasis symptoms observed after oral treatment with baricitinib

Read More

FDA approves Xolair for chronic idiopathic urticaria

Read More

CHMP issues positive opinion for simeprevir in chronic HCV infection

Read More

Efient approved in Japan for patients with ischemic heart disease undergoing PCI

Read More

Xtandi approved in Japan for castration-resistant prostate cancer

Read More

Health Canada approves Alprolix for hemophilia B

Read More

Lonsurf approved in Japan for recurrent colorectal cancer

Read More

EMA committee recommends approval of Vynfinit and companion imaging agents

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing